nach oben

Erschienen in:

2010 | OriginalPaper | Buchkapitel

17. European Regulations

verfasst von : Eleftheria Kampa, Thomas Dworak, Cornelius Laaser, Rodrigo Vidaurre

Erschienen in: Green and Sustainable Pharmacy

Verlag: Springer Berlin Heidelberg

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

This chapter reviews key existing policy instruments and approaches at EU level that are relevant to limiting the discharge of pharmaceutical products (PPs) into the aquatic environment. EU policies treated in this review address issues of authorisation of PPs, pollution prevention, wastewater treatment as well as monitoring of environmental quality. The analysis serves as a basis for the identification of potential gaps in current approaches. Future policy action might build on this assessment in order to reduce the risk of harmful impacts to the environment.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Experiences with the Swedish Environmental Classification Scheme

Nächstes Kapitel Regulation and the Market-Incentives

Guideline on the environmental risk assessment of medicinal products for human use. European Medicines Agency. London, 01 June 2006. Doc. Ref. EMEA/CHMP/SWP/4447/00.

Guidance for industry: Environmental Impact Assessment (EIAs) for veterinary medicinal products (VMPs). VICH International Cooperation for on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products. Phase I (VICH GL6) and Phase II (VICH GL38).

Minor changes to a drug marketing authorisation are in fact notifications, i.e. applicants just inform regulatory authorities and implement the changes without delay or approval. Examples are change in the name or address of the marketing authorisation holder or the manufacturer, change in the name of the medicinal product, change in the name of the active substance, minor change in the manufacturing process of the active substance, etc.

Examples of major changes to a drug marketing authorisation include change in the manufacturing process of the active substance that could affect efficacy, deletions in security information, deletions of contraindications, changes in adverse reactions, etc.

List I and II of Council Directive 76/464/EEC, Annex 1A and 1D of the Third North Sea Conference (3. NSC), Priority lists 1−3 identified under Council Regulation No 793/93, OSPAR list of individual candidate substances, HELCOM lists of priority substances, Pesticides prioritised under Council Directive 91/414/EEC, Monitored substances not mentioned on any of the lists above (based on the monitoring data obtained from Member States) (Klein et al. 1999, p. 7).

For example, trichloromethane (chloroform), trichloroethylene, tetrachloromethane, nonylphenol, naphthalene, mercury, dicloromethane, cadmium, chlorobenzene, anthracene, dicloroethane.

COM(2006) 398 final: Proposal for a Directive of the European Parliament and of the Council on environmental quality standards in the field of water policy and amending Directive 2000/60/EC.

European Parliament, Committee on the Environment, Public Health and Food Safety 2007: Compromise Amendments 1−3. Proposal for a Directive of the European Parliament and of the Council on environmental quality standards in the field of water policy and amending Directive 2000/60/EC. Draft report (PE 378.719v01-00), Anne Laperrouze. PE 386.558v01-00. 26.3.2007. http://www.europarl.europa.eu/meetdocs/2004_2009/documents/dv/659/659305/659305en.pdf

Directive 2008/105/EC on environmental quality standards in the field of water policy, amend-ing and subsequently repealing Council Directives 82/176/EEC, 83/513/EEC, 84/156/EEC, 84/491/EEC, 86/280/EEC and amending Directive 2000/60/EC.

“Main” in terms of amount introduced to the aquatic environment.

Bavaria has included as an aim in its waste management plan and in its development programme to abandon the use of sewage sludge in agriculture (cf. speech of State Secretary Dr. Otmar Bernhard at the international symposium on sewage sludge in June 2008, http://www.stmugv.bayern.de/aktuell/reden/detailansicht.htm?tid=14883)

Nordrhein-Westphalen aims to increase the amount of sewage sludge disposed of thermally, cf. Europäischer Wirtschaftsdienst Wasser und Abwasser, Nr. 11, 11.03.2008.

Bogaert P, Kingham R, Castle G, Molyneux CG (2007) REACH and its impact on pharmaceuticals. Covington E-Alert, Covington & Burling LLP. http://www.cov.com/files/Publication/ed03bc97-89de-471d-9163-4f1a26899ba2/Presentation/PublicationAttachment/e60742d7-e808-45a9-bec6-590676c12a9a/735.pdf

Callréus T (2005) The precautionary principle and pharmaceutical risk management. Drug Saf 28, 465−471

CEC – Commission of the European Communities (2004) Commission Staff Working Document on implementation of the Community Strategy for Endocrine Disrupters – a range of substances suspected of interfering with the hormone systems of humans and wildlife. COM (1999) 706

CHMP – Committee for Medicinal Products for Human Use (2006) Guideline on the environmental risk assessment of medicinal products for human use. CPMP/SWP/4447/00. European Medicines Agency, London

Clark J, Summerton L, Smith E, Kampa E, Touraud E (2007) Discussion Document on Ecopharmacostewardship of Pharmaceutical Products. KNAPPE Deliverable available at: http://www.knappe-eu.org/fichiers/47-D5.1%20Ecopharmacostewardship%20discussion%20document.pdf

Council Directive of 12 June 1986 on the protection of the environment, and in particular of the soil, when sewage sludge is used in agriculture (86/278/EEC). Official J L 181, 4/7/1986

Council Directive of 21 May 1991 concerning urban waste water treatment (91/271/EEC). Official J L 135, 30/5/1991

Council Directive 96/29/EURATOM of 13 May 1996 laying down basic safety standards for the protection of the health of workers and the general public against the dangers arising from ionizing radiation. Official J L 159, 29/6/1996

Council Directive 96/61/EC of 24 September 1996 concerning integrated pollution prevention and control. Official J L 257, 10/10/1996

Council Directive 97/43/Euratom of 30 June 1997 on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure, and repealing Directive 84/466/Euratom. Official J L 180, 9/7/1997, 22–27

Council Directive 98/83/EC of 3 November 1998 on the quality of water intended for human consumption. Official Journal L 330, 5/12/1998

Council Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official J L 136, 30/4/2004

CVMP – Committee for Medicinal Products for Veterinary Use 2007 Guideline on environmental impact assessment for veterinary medicinal products – in support of the VICH guidelines GL6 and GL38. EMEA/CVMP/ERA/418282/2005. European Medicines Agency, London

Directive 2000/60/EC of the European Parliament and of the Council establishing a framework for the Community action in the field of water policy. Official J L 327, 22/12/2000

Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products. Official J L 311, 28/11/2001, 1–66

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official J L 311, 28/11/2001 pp. 67–128

Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J L 136, 30/4/2004, 34–57

Directive 2004/28/EC of the European Parliament and of the Council of (31 March 2004 amending Directive 2001/82/EC on the Community code relating to veterinary medicinal products. Official J L 136, 30/04/2004, 58–84

Directive 2006/7/EC of the European Parliament and of the Council of 15 February 2006 concerning the management of bathing water quality and repealing Directive 76/160/EEC. Official J L 64, 4/3/2006

Directive 2006/118/EC of the European Parliament and of the Council of 12 December 2006 on the protection of groundwater against pollution and deterioration Official J L 372, 27/12/2006, pp. 19–31

Doerr-MacEwen NA, Haight ME (2006) Expert stakeholders’ views on the management of human pharmaceuticals in the environment. Environ Manag 38, 853–866CrossRef

Environment Agency (2003) Human Pharmaceuticals: Position Statement. http://www.environment-agency.gov.uk/aboutus/512398/289428/698017/?lang=_e

Holzmann T (2005) 2004 – ein wichtiges Jahr für die Umweltsicherheit von Arzneimitteln. Grußwort. In: Umweltbundesamt (ed.) 2005: Arzneimittel in der Umwelt – Zu Risiken und Nebenwirkungen fragen Sie das Umweltbundesamt. Texte 29-05. UBA. Dessau. 5–8

ICON – I C Consultants (2001) Pollutants in Urban Waste Water and Sewage Sludge. Final Report for DG Research. http://ec.europa.eu/environment/waste/sludge/pdf/sludge_pollutants_xsum.pdf

Jones OHA, Green PG, Voulvoulis N, Lester JN (2007) Questioning the excessive use of advanced treatment to remove organic micro-pollutants from waste water. Environ Sci Technol, 41 (14), 5085–5089CrossRef

Kemp R (2002) Treatment of an EU directive: UWWTD, Compliance with the Urban Waste Water Treatment in Germany, Spain, England and Wales, and The Netherlands. Books on Demand, Norderstedt, Germany

Klein W, Denzer S, Herrchen M, Lepper P, Mueller M, Sehrt R, Storm A, Volmer J (1999) Revised proposal for a list of priority substances in the context of the water framework directive (COMMPS Procedure). Schmallenberg (Deutschland), Fraunhofer-Insitut: 97

Knacker T, Liebig M, Moltmann JF (2006) Environmental risk assessment. In: Ternes TA, Joss A (eds.) Human Pharmaceuticals, Hormones and Fragrances. The Challenge of Micropollutants in Urban Water Management. IWA Publishing, London, Seattle, pp. 121–147

Koschorreck J, Apel P (2006) A brief overview on the legal background and the regulatory instruments of the environmental risk assessment for pharmaceuticals in the EU, USA, Japan, Australia and Canada. In: Ternes TA, Joss A (eds.) Human PharmaceuticalsHormones and Fragrances. The Challenge of Micropollutants in Urban Water Management. IWA Publishing, London, Seattle, pp. 107–119

Kümmerer K (ed.) (2004) Pharmaceuticals in the Environment. Sources, Fate, Effects and Risks. 2nd edition, Springer, Berlin, Heidelberg, New York

Kümmerer K (ed.) (2008a) Pharmaceuticals in the Environment. Sources, Fate, Effects and Risks. 3rd edition, Springer, Berlin, Heidelberg, New York

Kümmerer K (2008b).Strategies for reducing the input of pharmaceuticals into the environment. In: Kümmerer K (ed.) Pharmaceuticals in the Environment. Sources, Fate, Effects, and Risk. 3rd edition, Springer, Berlin, Heidelberg, New York, p. 411CrossRef

Kümmerer K, Schuster A (2008) Substance flows associated with medical care – Significance of different sources. In: Kümmerer K (ed.) Pharmaceuticals in the Environment. Sources, Fate, Effects, and Risk. 3rd edition, Springer, Berlin, Heidelberg, New York, p. 43CrossRef

Montforts M (2005) Vorsorge vor Umweltrisiken in der Produktinformation von Veterinärpharmaka: Juristische Fallstricke und Methodologische Herausforderungen. In: Umweltbundesamt (ed.) Arzneimittel in der Umwelt – Zu Risiken und Nebenwirkungen fragen Sie das Umweltbundesamt. Texte 29-05, UBA, Dessau

Niquille A, Bugnon O (2008) Pharmaceuticals and environment: Role of community pharmacies. In: Kümmerer K (ed.) Pharmaceuticals in the Environment. Sources, Fate, Effects, and Risk. Springer, Berlin, Heidelberg, New York, p. 467CrossRef

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official J L 136, 30/4/2004

Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Official J L 396, 30/12/2006

Roorda J, Derksen A, Wortel N (2008) Challenging conventional sanitation options for health care units. Presentation at the International Conference on New Sanitation Concepts and Models of Governance [19-21.05.2008], Wageningen. Available online: http://www.sanitation-challenge.wur.nl/UK/Conference+Presentations/

Schlimm J (2005) Umweltbewertung von Arzneimittel in Deutschland – ein kurzer Abriss. In: Umweltbundesamt (ed.) Arzneimittel in der Umwelt – Zu Risiken und Nebenwirkungen fragen Sie das Umweltbundesamt. Texte 29-05, UBA, Dessau, pp. 5–8

SRU – Sachverständigenrat für Umweltfragen (ed.) (2007) Arzneimittel in der Umwelt. Stellungnahme. Nr 12, April 2007. SRU, Berlin

Stuer-Lauridsen F, Birkved M, Hansen LP, LützhØft HC, Halling-Sørensen B (2000) Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere, 40, 783–793CrossRef

Umweltbundesamt (ed.) (2005) Arzneimittel in der Umwelt – Zu Risiken und Nebenwirkungen fragen Sie das Umweltbundesamt. Texte 29-05, UBA, Dessau

Van-Camp L, Bujarrabal B, Gentile A-R, Jones RJA, Montanarella L, Olazabal C, Selvaradjou S-K (2004) Reports of the Technical Working Groups Established under the Thematic Strategy for Soil Protection. EUR 21319 EN/6, 872 pp. Office for Official Publications of the European Communities, Luxembourg

VICH (2001) Guidance for Industry – Environmental Impact Assessments (EIAs) for Veterinary Medicinal Products (VMPs) – Phase I, VICH GL6, Final Guidance. US Department of Health and Human Services, Food and Drug Administration, Rockville

Wenzel H, Larsen HF, Clauson-Kaas J, Høibye L, Jacobsen BN (2008) Weighing environmental advantages and disadvantages of advanced wastewater treatment of micro-pollutants using environmental life cycle assessment. Water Sci Technol 57(1), 27–32CrossRef

Titel: European Regulations
verfasst von: Eleftheria Kampa
Thomas Dworak
Cornelius Laaser
Rodrigo Vidaurre
Verlag: Springer Berlin Heidelberg
Buch: Green and Sustainable Pharmacy
Print ISBN: 978-3-642-05198-2

Electronic ISBN: 978-3-642-05199-9

Copyright-Jahr: 2010
DOI: https://doi.org/10.1007/978-3-642-05199-9_17